


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Folestad et al
Serial No. : 09/806,795
Filed : April 4, 2001
For : METHOD AND APPARTUS FOR
MONITORING
Examiner : E. Tsoy
Group Art Unit : 1762

RECEIVED
CENTRAL FAX CENTER
MAR 21 2005

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. 1.8	
I hereby certify that this paper is being facsimile-transmitted to the U.S. Patent and Trademark Office on 21 March 2005 at the facsimile number <u>703-872-9306</u> .	
John M. Genova	32.224
Agent Name	PTO Reg. No.
	21 March 2005
Signature	Date of Signature

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

ATTENTION: Examiner Elena Tsoy
DATE: 21 Mach 2005
NUMBER OF PAGES: 3
FAX NUMBER: 703-872-9306

TERMINAL DISCLAIMER

Sir:

AstraZeneca, a corporation created and existing under the laws of Sweden, and having a business address at S-151 85 Södertälje, Sweden, hereby through its undersigned agent, who is empowered to act on behalf of AstraZeneca, represents that AstraZeneca is the owner of the entire right, title and interest of the above-identified patent application Serial No. 09/806,795, by Assignment recorded on April 4, 2001 at Reel 012363, Frame 0463.

The undersigned agent also represents that AstraZeneca is the owner of the entire right, title and interest of US 6,633,792, by Assignment recorded on September 9, 1999 at Reel 014091, Frame 0776, and a Change of Name recorded on December 15, 2000 at Reel 011389, Frame 0994.

AstraZeneca, by its undersigned agent, states that all evidentiary documents have been reviewed and certifies that, to the best of its knowledge and belief, title to Application Serial No. 09/806,795 and US 6,633,792 is in AstraZeneca. The inventions claimed in Application Serial No. 09/806,795 and US 6,633,792 were commonly owned by AstraZeneca at the time the later invention was made.

AstraZeneca hereby disclaims, except as provided below, the terminal portion of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term as defined in 35 U.S.C. §§154 to 156 and 173 of US 6,633,792 as presently shortened by any terminal disclaimer. AstraZeneca hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period it and US 6,633,792 are commonly owned. This agreement runs with any patent granted on the above-identified application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§154 to 156 and 173 of US 6,633,792, as presently shortened by terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is

statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims canceled by a reexamination certificate, is reissued or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Authorization is hereby given to charge Deposit Account No. 23-1703 in the amount of One Hundred and Thirty Dollars (\$130.00) to cover the fee as required by 37 C.F.R. §1.20(d) and for any other fee that may be required in connection with this communication.

Dated: March 21, 2005

Respectfully submitted,



John M. Genova
Reg. No. 32,224
Attorney Direct Dial (212) 819-8832

Client No. 007470
White & Case, LLP